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Abstract
Background: Infection with multiple CMV strains is common in immunocompromised hosts, but its occurrence in normal
hosts has not been well-studied.
Methods: We analyzed CMV strains longitudinally in women who acquired CMV while enrolled in a CMV glycoprotein B (gB)
vaccine trial. Sequencing of four variable genes was performed in samples collected from seroconversion and up to 34
months thereafter.
Results: 199 cultured isolates from 53 women and 65 original fluids from a subset of 19 women were sequenced. 51 women
were infected with one strain each without evidence for genetic drift; only two women shed multiple strains. Genetic
variability among strains increased with the number of sequenced genetic loci. Nevertheless, 13 of 53 women proved to be
infected with an identical CMV strain based on sequencing at all four variable genes. CMV vaccine did not alter the degree
of genetic diversity amongst strains.
Conclusions: Primary CMV infection in healthy women nearly always involves shedding of one strain that remains stable
over time. Immunization with CMVgB-1 vaccine strain is not selective against specific strains. Although 75% of women
harbored their unique strain, or a strain shared with only one other woman, 25% shared a single common strain, suggesting
that this predominant strain with a particular combination of genetic loci is advantageous in this large urban area.
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Introduction
Genetic variability among human cytomegalovirus (CMV)
isolates is a well-known feature that has been used to link viral
isolates epidemiologically and to determine the presence of
secondary/new CMV infections. Molecular studies of infected
infants and their mothers, children in day care centers, and organ
transplant patients led to the conclusion that CMV isolates that
were identical had a common source and that recovery of different
strains from the same person implied infection with a secondary/
new CMV strain [1–5]. Sequencing studies of CMV isolates have
usually been limited to one or several genes often with the aim of
identifying genotypes associated with virulence properties in
immunocompromised patients or infants with congenital infection
[6–8]. These studies provided information on genetic polymor-
phisms and geographical distribution of CMV genes, and the
presence of secondary/new CMV strains. Most of these studies
were based on genotyping cultured isolates of CMV from cross-
sectional, convenience samples with limited or no longitudinal
study and uncertainty as to when the study subjects acquired
CMV.
While infection with multiple CMV strains is frequently
reported in immunocompromised hosts, data in immune compe-
tent individuals is more limited. A key question in defining
infection with a new CMV strain is whether multiple strains are
acquired simultaneously at the time of initial infection or whether
a single CMV strain is involved. To address this question, a cohort
of healthy seronegative women who participated in a CMV
glycoprotein B (gB) vaccine clinical trial were followed until they
acquired CMV and for up to 34 months afterwards. CMV
genotyping was based on direct PCR sequencing at several distinct
gene loci including UL55, UL144, UL146 and UL09 from
different body fluids collected at intervals after infection. In
addition, it was possible to compare strains sequenced directly
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15949from body fluids to those sequenced after cell culture isolation, to
address whether growth in culture might select for strains that




Strain. Overall description of viral genomic structure based
on the sum of all loci tested. Strains can be distinguished from one
another by differences in one locus or multiple loci.
Genotype. A combination of subtype designations based on
sequence data obtained from two or more gene loci.
Subtype. Cluster pattern based on sequence data at any one
gene locus.
Variant. Minor nucleotide changes observed within a subtype.
Isolate. CMV recovered from a human specimen and
passaged in culture a limited number of times.
Demographics and samples
The study population was from the Birmingham, Alabama
metropolitan area. The mean age of subjects was 19.6 years (range
15.3–33.9); 83% were African American and 17% were white,
non-Hispanic. The time of infection was estimated to be the
midpoint of the interval during which seroconversion was
detected. All immunized women except one developed gB1
antibodies and neutralizing antibodies. CMV-infected women
who received placebo had all developed gB1 antibodies. The
median interval from time of infection to first viral cultures was 3
months. Cultures of specimens obtained within three months of
infection were available in 50 women. In 3 women cultures were
available only 6mo-18mo following seroconversion. Samples were
available for PCR sequencing during follow-up of up to 34 months
in 43 women. The average time between the first and last sample
available for PCR sequencing was 10 months (Fig. 1).
A total of 199 tissue culture isolates of CMV from urine, saliva
and vaginal fluid, from 53 women (range 1–13, average 3.8/
participant; table 1) and 65 original fluids including urine, blood,
vaginal and oral specimens from 19 women (range 1–7, average
3.4/participant) were analyzed. Of 53 women, 23 provided more
than 4 isolates over time. These isolates always had an identical
strain in the same woman. In cases where more than 3 samples
were tested over time (n=32, table 2) at least one body site was
available for sequential testing.
One strain vs. multiple strains
A single CMV strain was detected in each of 51 women based
on UL55 and UL144 sequencing from two or more isolates
separated in time of collection by at least one month. The interval
between the earliest and last isolates tested ranged from 1 to 34
months (median, 8 months). Isolates collected at 2 to 4 different
points in time were available from 41/51; 21/51 had isolates from
.4 different time points. In each of these 51 women the same
strain was present in each isolate tested with no evidence of
acquisition of new strains or of sequence changes based on testing
of multiple genetic loci as described below.
Two of 53 participants were infected with multiple strains. In
one of them, saliva and urine were available only at 18 months
after seroconversion. Two different strains were detected, one in
each fluid. To assess whether the two strains might occur in both
fluids with one being more abundant than the other and therefore
not detected by direct sequencing, PCR products obtained from
saliva and urine were cloned into plasmids, and 20 independent
colonies were picked from each site for sequencing. There was no
evidence for low abundance strains existing along the predominant
strain based on sequencing of 20 colonies. The second participant
with two strains provided oral fluid near seroconversion in which
only one strain was detected. Twelve months later a new strain was
found in three urine samples while the original oral strain was
unchanged. Sequencing of 20 plasmid clones from these PCR
Figure 1. Interval (in months) between first and last sample tested by PCR. Samples available for PCR sequencing were collected from CMV-
infected women at different times following seroconversion.
doi:10.1371/journal.pone.0015949.g001
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the major strain.
Variability within specific genetic loci
Our definition of CMV subtypes and genotypes is based on an
extensive multilocus analysis of independent genomes obtained
from a wide range of different clinical sources and of geograph-
ically diverse human populations (Zong JC, Alcendor DJ, Arav-
Boger R, and Hayward GS, unpublished data). For the present
study we chose to analyze four particular variable gene loci: the
most commonly studied UL55/gB, of which one subtype (gB-1) is
the vaccine strain, the truncated TNFa receptor-like gene UL144
[9], and the alpha chemokine ligand UL146, the most variable of
all CMV genes with 14 known subtypes [10,11]. Finally, in 13
women we also examined UL09, encoding a moderately variable
protein with eight subtypes that is located on the other side of the
UL region from UL144 and UL146.
Five subtypes of gB were found among study participants with
nucleotide polymorphisms between them ranging from 28
to124 bp. Subtype 1 contained three minor variants that differed
from one another by 1, 4, and 5 nucleotides. Subtype 2 had two
variants that differed by one nucleotide. Subtype 3 had two
variants that had five nucleotide changes (Fig. 2 for amino acid
alignment). There were no minor variants of subtypes 4 and 5. We
judge the one nucleotide change to represent a genuine distinct
variant rather than Taq polymerase error, because we have already
identified this specific variant in other patient populations [4].
There were three UL144 subtypes (A, B, and C) and a
recombinant group A/C (Fig. 3). Nucleotide changes between
these subtypes ranged from 35–100 bp. There were five variants of
UL144 subtype B (B1-4, and B6), with 1 to14 nucleotide changes
between these variants. Subtype A included two variants, A1 and
A2 that differed by 17 bp. Phylogenetic analysis of gB and UL144
DNA subtypes among vaccine and placebo recipients appear in
Fig. 4.
There were also nine highly diverged subtypes and three
variants of UL146 (Fig. 5) similar to those seen in other studies
[10,12]. No nucleotide variations were observed amongst the
viruses present in samples from different body fluids from the same
participant. There was also no evidence for any subtype being
found preferentially in a particular type of body fluid.
Correlation between original fluids and cultured isolates
We sequenced UL55 and UL144 directly from original fluids
and after propagation in cell culture from 19 participants in whom
adequate original fluids were available. DNA sequence data
obtained from cultured isolates matched the sequences obtained
from original fluids.
Minor CMV strains
There was no evidence for mixed infections in any samples
examined by direct PCR sequencing. To further examine whether
low abundance strains might exist but not observed by our
population based sequencing, PCR products were cloned from 12
cultured isolates and from 10 original fluids, and 10 to 20 colonies
each were picked for sequencing. In all cases, the parent strain
obtained from direct sequencing of the PCR product was also
found in sequences of all the cloned plasmids, with no evidence for
any minor strains being present. Thus we judge that any low
abundance strains that might be present were below a level of 5
to10% of the abundance of the major strain.
Clonal infection
The number of distinguishable CMV strains detected in this
study increased with the number of sequence loci analyzed. To
resolve situations in which multiple subjects appeared to share the
same strain additional genetic loci were sequenced. Based on
UL55 alone, only 5 subtypes were found amongst the 53 women,
but combining UL55 and UL144 subtypes yielded 27 genotypes
(Fig. 6, table 2). At this level of analysis, 16 women were infected
with a distinct UL55/UL144 genotype that was different from all
other genotypes, whereas 37 participants fell into one of 11
different genotypes; each genotype was detected in 3 or 4 women,
but one genotype was noticed in 13 women (Fig. 6, table 2).
To further resolve these 11 genotypes shared between the 37
participants we also sequenced the hypervariable UL146 gene
locus. Adding the UL146 data revealed a total of 22 different
genotypes; 16 women with identical UL55/UL144 genotype each
had different unique UL146 subtypes. There were five pairs of
women in which each pair shared a common UL146 sequence
that was different from any of the other pairs (Fig. 6, table 2), as
well as 13 women with the same UL55/UL144 who still shared
exactly the same identical UL146 sequence. Therefore, the total
number of women with their own unique strain based on triple loci
UL55/UL144/UL146 sequencing was 32, whereas ten women
shared five paired strains, and yet another 13 women were infected
with the same strain based on sequencing of the UL55/UL144/
UL146 loci (genotype 5/B2/G9). Furthermore, sequencing of the





per subject Source of isolates
10 1 7 urine, 2 saliva, 1 vaginal
11 2 13 urine, 5 saliva, 4 vaginal
9 3 17 urine, 6 saliva, 4 vaginal
23 $4 66 urine, 47 saliva, 27 vaginal
doi:10.1371/journal.pone.0015949.t001
Table 2. CMV strains detected in 53 CMV-infected women.
1/B1/G1 1/B1/G13 1/B1/G7 1/B2/ND 1*/A/ND
1*/B4/G5 1*/B4/G5 1*/B4/G7 1*/B6/ND 1**/A/ND
1**/A1C1/ND 1**/B1/ND 1**/B3/G11 1**/B3/G11 1**/B3/G11*
1**/B3/G11* 1**/B4/ND 2/A1C1/ND 2/A2/ND 2/B1/G13
2/B1/G9 2/B3/ND 2/B4/G13 2/B4/G7 2/B4/G7
2/C/ND 3*/B4/ND 3/A1/G1 3/A1/G12 3/A1C1/ND
3/B3/G8 3/B3/G8 3/B4/ND 3/C1/G11 3/C1/G13
3/C1/G8* 4/A1/G13 4/A1/G14 4/B1/ND 4/B4/G7
4/B4/G9* 5/B2/G9 5/B2/G9 5/B2/G9 5/B2/G9
5/B2/G9 5/B2/G9 5/B2/G9 5/B2/G9 5/B2/G9
5/B2/G9 5/B2/G9 5/B2/G9 5/B2/G9 5/C1/ND
Strain designations are based on the combined UL55/UL144/UL146 genotype.
The strains were ordered from 1 to 5 based on UL55 subtypes and variants.
UL146 subtypes given here are based on Dolan’s nomenclature [10]. Bold
entries are strains from vaccine-recipients. ND represents cases where a strain
could be resolved based on UL55/UL144 only and UL146 sequencing was not
attempted.
doi:10.1371/journal.pone.0015949.t002
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subtype UL09-C with identical nucleotide sequences in all.
Confirmation of sequencing data in a second laboratory
To completely rule out any potential source of artefactual
laboratory contamination within or among the samples from these
13 participants who shared the same virus, we sequenced UL55
and UL144 from original fluids of 11 of the 13 participants. In all
cases the results matched those obtained from cultured isolates. In
addition, seven coded cultured isolates were sent directly from
Alabama to a laboratory in Korea (Ahn JH) for independent DNA
extraction, PCR and sequencing. Six of these samples were among
Figure 2. Alignment of gB subtypes. Amino acid alignment encompassing the proteolytic cleavage site of gB subtypes detected in the 53 CMV-
infected women. Variants with amino acid changes within a subtype are depicted: gB1 (1 and 1**), and gB3 (3 and 3*). The gB1 prototype is Towne,
gB2 prototype is AD169, and gB3 prototype is Toledo. The gB1* and the two variants of gB2 are associated with nucleotide changes only.
Considering the five major gB subtypes, the two women with multiple strains had gB5/gB1, and gB4/gB1. The subtype distribution among the 51
women who shed one strain was as follows: 15 women shed gB1 (including variants), 9 women - gB2, 10 women - gB3, 4 women - gB4 and 13
women -gB5.
doi:10.1371/journal.pone.0015949.g002
Figure 3. Alignment of UL144 subtypes. Amino acid alignment of full-length UL144 subtypes A, B, C, A/C. Among the 51 women who shed one
viral strain the distribution of UL144 subtypes was: 6 women -UL144A, 7 women - UL144B1, 14 women - UL144B2, 6 women - UL144B3, 10 women -
UL144B4, 1 woman - UL144B6, 3 women - UL144A1/C1 and 4 women - UL144C. The women with multiple strains had C/B3, and A1/B1. Please also
refer to the phylogenetic tree, figure 4a.
doi:10.1371/journal.pone.0015949.g003
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and in black- placebo recipients.
doi:10.1371/journal.pone.0015949.g004
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was from a woman infected with a different strain. After uncoding,
the resulting genotypes again completely matched the data
obtained in our Baltimore laboratory.
Comparison of CMV strains in vaccine and placebo
recipients
A high level of strain diversity was observed among both vaccine
and placebo recipients. While some strains were shared between
the two groups, others appeared only in the vaccine or in the
placebo group (Fig. 5a, b, Table 2). The dominant strain 5/B2/
G9/C, shared by 13 participants, was equally distributed among
vaccine and placebo recipients. Among the two participants with
multiple strains one received vaccine and the other received
placebo.
Discussion
We have shown that acquisition of multiple CMV strains at the
time of primary infection is rare in healthy young women. Within
the short period after primary CMV infection, shedding of a single
CMV strain appeared to be the rule, and the same strain was
detected from multiple different body sources in each participant
Figure 5. alignment of UL146 subtypes. Amino acid alignment of UL146 subtypes. Subtype definition by Dolan et al (10) appears in parentheses.
Several variants in Dolan’s subtypes G8, G9, andG11have been detected in this cohort andaredesignated E1, E2, G1, G2, H1, andH2 based on common
patterns of a small number of nucleotide and amino acid polymorphisms. Among 37 women the distribution of UL146 subtypes was: 14 women - G9, 1-
G9*, 5 - G7, 5 - G13, 3 - G11, 2 - G11*, 2 - G8, 1- G8*, 2 - G5, 2 - G1, 1 - G12, and 1- G14. The women with multiple strains had G8*/G11, and G13/G14.
doi:10.1371/journal.pone.0015949.g005
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sequencing in original fluids completely matched strains detected
after propagation in cell culture. Surprisingly, although most
women had their own unique strain, 25% of women enrolled in
the study at different times and with no known epidemiologic links
shared exactly the same CMV strain based on sequencing of four
variable genetic loci.
In contrast to our findings in these recently infected healthy
women, multiple CMV strains have been detected in AIDS
patients [13], and transplant recipients [3,14]. Previously CMV-
seropositive transplant recipients became infected with new CMV
strains from their donors [14]. Multiple CMV strains were
detected in blood from 5 of 11 CMV-infected renal transplant
patients [15]. In that study, all five patients were seronegative prior
to transplantation, suggesting that normal seropositive donors may
harbor and transmit multiple CMV strains or that the transplant
recipients were susceptible to multiple exposures. In addition to
acquisition of new strains over time, replacement of strains can
also occur [16]. Immunocompromised hosts can become a
reservoir for generation of new CMV strains in-vivo through
recombination [17].
In all cases except two the same virus strain was observed in all
body fluids available from the same participant. These two
participants had two different strains each, but each strain was
detected in a specific body fluid. Because of limited sample
availability from these two women, we are unable to determine
whether infection with both strains might have occurred around
seroconversion or that a second exposure occurred later than the
first. Compartmentalization of strains has been reported in
transplant recipients [3], in HIV populations [18,19], and a small
series of women with STDs [20]. Based on our findings in the two
women with multiple strains, the detection of a different virus in
one or more body sites suggests that a new strain was occasionally
able to overgrow the existing one so that the original one became
undetectable.
Multiple CMV strains have been reported far less commonly in
normal hosts and usually when repeated exposures to new sources
of CMV would be expected. For example, four of eight women
attending a sexually transmitted disease (STD) clinic excreted
distinct CMV strains simultaneously at different sites or shed new
strains when studied serially [20]. Infection with new CMV strains
has also been reported in children attending day care centers
[1,21]. Previously immune mothers may acquire a new CMV
strain during pregnancy and transmit it to their offspring [22]. We
have reported on the detection of multiple CMV strains in autopsy
tissues after in-utero death as a result of disseminated CMV
infection [4]. One recent report on strain diversity in healthy
CMV-seropositive women suggested that 15/16 women who
tested PCR positive (total 2.9% PCR positivity in that cohort) were
infected with more than one strain based on genotyping
glycoproteins gN and gB from blood or urine samples [2].
However, the time of primary infection was unknown in these
women, so it is not possible to draw conclusions as to diversity or
homogeneity of CMV strains acquired around seroconversion. In
addition, the detection of multiple genotypes from blood samples
in that cohort may suggest that this specific population was at risk
for infection with multiple strains. However, information on
potential risks or immunodeficiencies was not available.
The importance of sequencing CMV genomes from original
fluids stems from knowledge in CMV biology that clinical isolates
undergo genetic changes and selection during passage in cell
culture [23], and that initial load may determine growth rate. In
our study there was no mismatch between strains sequenced from
original fluids and strains sequenced from cultured isolates. Since
we did not find multiple strains in original fluids we were unable to
determine whether culture may select for strains that grow more
efficiently.
Surprisingly, we found a completely identical CMV strain in 13
of 53 women who had no obvious epidemiological links. This
result was based on sequencing at four widely spaced and variable
loci (UL55/UL144/UL146/UL09). While identity occurs when
comparing different viral strains at one or even two loci, multi-
locus identity between four variable genes has never been reported
between unrelated individuals. Although we cannot completely
rule out the possibility that the single strain shared between the 13
women may prove to be distinct if sequence data from other genes
becomes available, this seems extremely unlikely based on the
known patterns of genetic variability within the chosen genes.
Figure 6. Breakdown of strain diversity in the study cohort based on sequencing of three hypervariable CMV genes. * The two
women with two strains each had one unique strain (based on UL55/UL144) and one shared strain.
doi:10.1371/journal.pone.0015949.g006
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genetic locus and assuming these subtypes are randomly
distributed in the population, the probability that 13 of 53 women
will be shedding the same strain is remote, unless a common
source or exposure has been involved. Therefore, the wide
occurrence of a single genetically identical strain amongst isolates
across our study suggests that specific combinations of genotypes
are not randomly distributed and may be detected more
commonly within a constrained geographical area and time
frame. We note that the same strain (5/B2/G9) was already
detected nearly a decade ago in 2 of 21 neonates born in the
Birmingham Metropolitan area with congenital CMV disease,
AMS3 and SUR9 [4]. Upon additional sequencing these two
strains also proved to be identical to each other at the nucleotide
level over an additional 8,000-bp encompassing nine more highly
variable genes RL05, RL06, RL12, RL13, UL01, UL37ex3,
UL73, UL74 and UL120, as well as being identical to each other
and to the 13 from the current study in UL09 (Hayward GS and
Arav-Boger R, unpublished data). An Italian study that investi-
gated transmission of CMV strains in 13 pregnant women and
their families revealed that the detection of a single strain in
original fluids or viral isolates was the rule, in agreement with our
findings [24]. In each family, an identical strain was found based
on UL55/UL144/UL146. Although strains from different families
were usually distinct from one another, when comparing data
from uni-locus sequencing, identical UL146, UL144 or UL55
DNA were observed sporadically among unrelated subjects.
The data presented here is based on PCR sequencing of viruses
that were shed in different body fluids. We cannot completely
exclude the possibility that some women were infected over time
with new strains that were not shed. Type-specific serological
methods (for gB and gH) are currently being developed [25,26],
and once their sensitivity and specificity is validated, they could be
used to address this question in other more appropriate cohorts.
We conclude from this comprehensive sequencing project that:
1. Primary CMV infection in healthy young women predomi-
nantly involves one CMV strain as detected in both cultured
isolates and original fluids. 2. Each strain remains stable at least
during the first 2.5 years, albeit sampling only 1–2% of the CMV
genome. 3. Shedding of multiple strains is evidently rare in the
normal host over a period of several years. 4. Immunization with a
CMV glycoprotein B subunit vaccine did not alter the distribution
of CMV strains, and did not select for infection with particular
viruses. 5. An unexpected finding was that a subgroup of women
were infected with the same virus based on sequencing of four
widely distanced genetic loci, suggesting that a viral strain
containing specific combinations of variable genes may be
advantageous and occur more commonly than other viral strains
with different genetic makeup.
Methods
Study population
The study population was comprised of 53 women who
acquired CMV infection while participating in a phase 2,
randomized, double-blind, placebo controlled clinical trial of a
CMV vaccine [27]. Clinical trial participants were CMV
seronegative, healthy young women. They were immunized with
CMV gB (based on Towne, gB-1 subtype) vaccine (Sanofi Pasteur,
Marcy L’Etoile, France) with MF59 adjuvant (Novartis, Boston,
MA) on a 0, 1 and 6 month schedule and were screened for CMV
infection every three months for 3.5 years using an antibody assay
which detects seroconversion to CMV proteins other than gB [28].
Institutional review board approval was obtained from University
of Alabama at Birmingham and Johns Hopkins Hospital and all
subjects signed an approved consent form.
Viral isolation
Subjects with serologic evidence of infection were tested for
CMV in blood, urine, saliva and vaginal swab from one month to
3.5 years after detection of infection. Aliquots of each specimen
were stored at 280uC. Fresh urine, saliva and vaginal swab
specimens were inoculated into cultures of MRC-5 cells (ATCC)
or locally prepared human foreskin fibroblasts. Cultures were
checked weekly for 4–6 weeks after inoculation; CMV was
identified by its characteristic cytopathic effect. Tissue culture with
CMV (primary isolate or first passage) was frozen at 280uC.
DNA extraction and PCR amplification
Total genomic DNA was extracted from infected cells using a
capture-column kit (Qiagen, Valencia, CA). CMV DNA was
extracted from 400 mL of original samples - blood, urine, saliva or
vaginal swab - using the MagAttract virus mini M48 kit (Qiagen,
Valencia, CA) on Biorobot M48. Initially, UL55 (gB) and UL144
were amplified from all cultured isolates and from available
original fluids. To further define strain diversity in participants
that appeared to share the same genotype based on the combined
UL55/UL144 data, UL146 was also amplified from 45 of these
women. Finally, UL09 was amplified from 13 women who shared
the same genotype based on UL55/UL144/UL146 data.
Primers for PCR amplification were reported [4,29] or appear
in Table 3. The sizes of the amplified loci were: 400 bp
encompassing the proteolytic cleavage site of UL55, and 531 bp,
480 bp, and 687 bp representing the full length UL144, UL146
and UL09 protein coding regions. The reaction mixture consisted
of 45 mL supermix (Invitrogen, Carlsbad, CA) 1 mL DNA, and
1 mL of each primer (10 mM). PCR reactions were set up in a
dedicated, non-CMV laboratory. PCR products were separated by
agarose gel electrophoresis. Appropriate DNA fragments were
excised, purified using QIA quick gel extraction kit (Qiagen) and




UL144 nested forward 59-CTTCCGGTAGGAGGCATGAAG-39
UL144 nested reverse 59-GACTTCATCGTACCGTGATC-39
UL146-147 forward 59- GTCATGGACGCAGTTTTG-39
UL146-147 reverse 59- GAACGATCTCGTCCGGTTC-39
UL146 hemi-nested reverse 1 59- CTAAAASATGGACGGCTAGG-39
UL146 hemi-nested reverse 2 59- GTCGTAATCTTCCARTTC-39
UL55 forward 59-TCCGAAGCCGAAGACTCGTA-39
UL55 reverse 59-GATGTAACCGCGCAACGTGT-39
UL55 nested forward 59-CATAGGTGAACTGCAGCTG-39
UL55 nested reverse 59-AGCATGGTGAAAAGAAGACG-39
UL09 forward 59-CATCTGTCTRCGAGCACCTC -39
UL09 reverse 59-GACCATCGGAAAAGATCATGG -39
UL09 nested forward 59-CAGTACGGACAAGTGTTYATG -39
UL09 nested reverse 59-GGTTCACGATATGGTTAATCAG -39
doi:10.1371/journal.pone.0015949.t003
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direct sequencing with the same primers used for PCR.
Cloning
In selected cases PCR products were also cloned and then
sequenced. PCR reactions designated for cloning were obtained
using high fidelity PCR supermix (Invitrogen, Carlsbad, CA). PCR
products were cloned into Zero Blunt Topo (Invitrogen). Following
ligation and transformation into E.coli cells, 20 recombinant
colonies were picked and grown overnight at 37uC in LB broth
containing 50 mg/mL kanamycin. Plasmid DNA was purified using
High Pure Plasmid Isolation Kit (Roche, Pleasanton, CA), and
plasmid inserts were sequenced with universal primers.
Sequencing
Purified PCR products were sequenced using the BigDye
Terminator Cycle Sequencing Kit (Perkin-Elmer Applied Biosys-
tems, Foster City, CA). Sequencing products were analyzed with
an ABI 3100 automated sequencer (Applied Biosystems). Nucle-
otide and amino acid sequences of clinical CMV strains and
reference Towne, Toledo and AD169 strains were aligned using
ClustalW [30] and MAFFT [31]. Phylogenetic trees were con-
structed using the neighbor- joining method in Mega4 [32].
GenBank accession numbers
UL55- GU365817-GU365825, UL144- GU365826-GU365834,
UL146- GU365835-GU365846, and UL09- HM542481.
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